We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Team Discovers New Drug Binding Site on Ebola and Marburg Viruses

Team Discovers New Drug Binding Site on Ebola and Marburg Viruses

Team Discovers New Drug Binding Site on Ebola and Marburg Viruses

Team Discovers New Drug Binding Site on Ebola and Marburg Viruses

Cryo-electron tomographic image of a virus-like particle displaying Ebola virus surface spikes (top) and visualization of their three-dimensional structure (bottom). Credit: Veronica Falconieri, Sriram Subramaniam/ National Cancer Institute
Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Team Discovers New Drug Binding Site on Ebola and Marburg Viruses"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ebola and Marburg are among the most deadly viruses, with mortality rates from these infections ranging from 25% to 90%. While no drugs currently are available on the market to prevent infection from these viruses -- they belong to a category of viruses called filoviruses, which are known to cause hemorrhagic fever -- researchers have identified a few small drug molecules that can block filoviruses from infecting cells by occupying a single site on a glycoprotein in the virus.

Now, researchers at the University of Illinois Chicago have identified a second site on the filovirus glycoprotein to which small drug molecules can bind and prevent infection. The researchers say that small drug molecules that block both glycoprotein sites may be more effective and reduce the risk of side effects.

These findings are reported in the journal PLOS Pathogens.

"We need to identify how these filoviruses get into cells as a means to help us identify or develop drugs that can prevent infection," said Lijun Rong, UIC professor of microbiology and immunology at the College of Medicine and a corresponding author of the paper. "Even though at the moment Ebola and Marburg are not in the news that often, having drugs in our arsenal in case of a flare-up is invaluable. These viruses also mutate constantly, so having a better understanding of how they work will let us develop next-generation viral inhibitors."

Rong's group and his collaborators, led by Rui Xiong, UIC research assistant professor of pharmaceutical sciences at the College of Pharmacy, identified the second glycoprotein binding site by pairing the virus with hundreds of different small drug molecules thought to possibly have an effect on viral entry into cells. Several of the drugs were able to prevent viral entry.

Through a series of experiments using molecular, biophysical and structural experimental techniques, they were able to look more closely at how these drugs were interacting with the virus. They found that the drugs were binding to a previously unknown site on the viral surface glycoprotein required for cell infection.

"The good news is that there are already drugs approved by the FDA that can bind to the new site we identified," Rong said. "If we can give drugs that bind to the site we newly identified and the site previously identified, it can help prevent viral infection with lower doses of each drug. Interfering with both sites on the viral surface glycoprotein, it also reduces the chances of the glycoprotein mutating to the point that it escapes the effect of the drug combination and is able to infect cells once again."

Reference: Schafer A, Xiong R, Cooper L, et al. Evidence for distinct mechanisms of small molecule inhibitors of filoviral entry. PLOS Pathog. 2021;17(2):e1009312. doi:10.1371/journal.ppat.1009312

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.